Sign inJoin waitlistJoin the waitlist

EP

Elisavet Paplomata

Hematology & Oncology

Credentials: · · · ·

History

Hematology and Medical Oncology
Emory University School of Medicine
2011–2014
Internal Medicine
2008–2011
Doctor of Medicine
1997–2001

Research

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
New England Journal of Medicine · 2020 · 1,022 citations
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Journal of Clinical Oncology · 2020 · 452 citations
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Review · Therapeutic Advances in Medical Oncology · 2014 · First of 2 authors · 444 citations

Ruth O’Regan
6 papers
Amelia Zelnak
5 papers
Eric Winer
4 papers
EH
Erika Hamilton
4 papers
Lisa Carey
4 papers
Rashmi Murthy
4 papers
Sara Hurvitz
4 papers
Virginia Borges
4 papers
Carey Anders
3 papers
Dennis Slamon
3 papers
Gabriel Hortobagyi
3 papers
IK
Ian Krop
3 papers

Clinical trials

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Principal investigator · Terminated · Phase 2
Emory University
2010–2015
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Principal investigator · Completed · Phase 2
Emory University
2009–2015
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Principal investigator · Completed · Phase 2
Emory University
2009–2017
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Principal investigator · Terminated · Phase 2
Emory University
2009–2015